Abstract
Sepsis is one of the most significant causes of morbidity and mortality in intensive care units. The incidence of sepsis is still frequent, and the high mortality rates associated with the disease is increasing in the critically ill. Worldwide, 13 million people become septic each year and 4 million die. The pathophysiology of sepsis remain an enigma and the natural history is ever evolving.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kenzaka T, Okayama M, Kuroki S et al (2012) Importance of vital signs to the early diagnosis and severity of sepsis: association between vital signs and sequential organ failure assessment score in patients with sepsis. Intern Med 51(8):871–876
Ron D, Tim N (2010) ABC of Sepsis. Edited by Blackwell Publishing. ISBN: 978-1-4501-8194-5
Riedemann NC, Guo Ren-Feng, Ward PA (2003) The enigma of sepsis. J Clin Invest 112(4):460–464
Balk BA, Bone RC (1989) The septic syndrome: definition and clinical implications. Crit Care Clin 5:1–8
Vincent JL (1997) Dear Sirs, I’m sorry to say that I don’t like you. Crit Care Med 25:372–374
Tulli G (2003) Critical points for sepsis management at the patient bedside. Minerva Anestesiologica 69(1–2):35–56, 56–65
Deitch EA (1993) Cytokines yes, cytokines no, cytokines maybe? Crit Care Med 21:817–819
Nguyen HB, Loomba M, Yang JJ et al (2010) J Inflamm (Lond)7:6. doi:10.1186/1476-9255-7-6
Nichol AD, Egi M, Pettila V et al (2010) Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multicentre study. Crit Care 14:R25
Nichol A, Bailey M, Egi M et al (2011) Dynamic lactate indices as predictors of outcome in critically ill patients. Crit Care 15(5):R242. doi:10.1186/cc10497
Tjardes T, Neugebauer E (2002) Sepsis research in the next millennium: concentrate on the software rather than the hardware. Shock 17(1):1–8
Knaus WA, Draper EA, Wagner DP et al (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829
Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22(7):707–710
Zügel NP, Kox M, Lichtwark-Aschoff M (2011) Predictive relevance of clinical scores and inflammatory parameters in secondary peritonitis. Bull Soc Sci Med Grand Duche Luxemb 1:41–71
Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31(4):1250–1256
Rubulotta F, Ramsay G (2012) Outcomes in severe sepsis and patients with septic shock do not matter! PIRO is a score to treat severe septic and septic shock patients not to measure outcomes. Crit Care Med 40(2):706–707; author reply 707–708. doi:10.1097/CCM.0b013e31823b8b03
Rivers E, Nguyen B, Havstad S et al (2001) (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377
Rivers EP, Nguyen HB, Amponsah D (2003) Sepsis: a landscape from the emergency department to the intensive care unit. Crit Care Med 31(3):968–969
Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296–327
Rivers EP, Ahrens T (2008) Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin 24(3 Suppl):S1–S47. doi:10.1016/j.ccc.2008.04.002
Gullo A, Bianco N, Berlot G (2006) Management of severe sepsis and septic shock: challenges and recommendations. Crit Care Clin 22(3):489–501, ix
Marshall JC, Maier RV, Jimenez M, Dellinger EP (2004) Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 32(11 Suppl):S513–S526
Assicot M, Gendrel D, Carsin H (1993) High serum procalcitonin concentration in patients with sepsis and infection. Lancet 341:515–518
Meissner M, Tschaikowsky K, Hutzler A et al (1998) Postoperative plasma concentration of procalcitonin after different types of surgery. Intensiv Care Med. 24:680–684
Deliberato RO, Marra AR, Sanches PR et al (2013) Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 76(3):266–271. doi:10.1016/j.diagmicrobio.2013.03.027
Assink-de Jong E, de Lange DW, van Oers JA et al (2013) Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitoninversus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients–calculated sample size: 1816 patients. BMC Infect Dis 13:178. doi:10.1186/1471-2334-13-178
Tauseef M, Knezevic N, Chava KR et al (2012) TLR4 activation of TRPC6-dependent calcium 4 signaling mediates endotoxin-induced lung vascular permeability and inflammation. J Exp Med 209(11):1953–1968. doi:10.1084/jem.20111355; the receptor for advance glycation end products (RAGE)
Chen YJ, Sheu ML, Tsai KS et al (2013) Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals end signals in human chondrocytes via toll-like receptor-4 and receptor for advanced glycation products. PLoS One 8(6):e666 11. doi:10.1371/journal.pone.0066611. Print 2013; and high mobility group box 1 (HMGB-1)
Diener KR, Al-Dasooqi N, Lousberg EL, Hayball JD (2013) The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol Cell Biol. doi:0.1038/icb.2013.25
Dellinger RP, Carlet JM, Masur H et al (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873
Dellinger RP, Carlet JM, Masur H et al (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30:536–555
Dellinger RP, Levy MM, Carlet JM, Bion J et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 36(1):296–327
Dellinger RP, Levy MM, Rhodes A, Annane D (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 41(2):580–637. doi:10.1097/CCM.0b013e31827e83af]
Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709. PROWESS Study
Dhainaut JF, Laterre PF, Janes JM et al (2003) Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29(6):894–903. Epub 24 Apr 2003
Abrahan PF, Laterre R, Garg et al (2005) Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low risk of Death. The N Engl J Med 353:1332–1341
Zambon M, Ceola M, Almeida-de-Castro R et al (2008) Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster. J Crit Care 23(4):455–460. doi:10.1016/j.jcrc.2007.08.003
de Jonge E, Schultz MJ, Spanjaard L et al (2003) Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 362(9389):1011–1016
Anonymous (2000)Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 342(18):1301–1308
Van den Berghe G, Wouters P, Weekers E et al (2001) Intensive insulin therapy in critically ill. N Engl J Med 345:1359–1367
Cronin I, Cook DJ, Carlet J et al (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439
Vandenbroucke-Grauls CM, Vandenbroucke JP (1991) Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet 338(8771):859–862
Liberati A, D’Amico R, Pifferi S et al (2009) Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 4:CD000022. doi:10.1002/14651858.CD000022.pub3
Silvestri L, van Saene HK, Milanese M et al (2007) Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect 65(3):187–203
Silvestri L, van Saene HK, Weir I, Gullo A (2009) Survival benefit of the full selective digestive decontamination regimen. J Crit Care 24(3):474.e7–474.e14
Silvestri L, de la Cal MA, van Saene HK (2012) Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth. Intensive Care Med 38(11):1738–1750. doi:10.1007/s00134-012-2690-1
Viviani M, Silvestri L, Van Saene HK et al (2008) My brother has severe sepsis. Should he receive selective decontamination of the digestive tract (SDD)? Minerva Anestesiol 74(9):507
Silvestri L, van Saene HK, Petros AJ (2012) Selective digestive tract decontamination in critically ill patients. Expert Opin Pharmacother 13(8):1113–1129. doi:10.1517/14656566.2012.681778]
Daneman N, Sarwar S, Fowler RA et al (2013) Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis pii:S1473-3099(12)70322-5. doi:10.1016/S1473-3099(12)70322-5
Proudfoot AG, McAuley DF, Hind M (2009) Translational research: what does it mean, what has it delivered and what might it deliver? Crit Care Med 37(1 Suppl):S10–S15. doi:10.1097/CCM.0b013e3181921497
Opal SM, Patrozou E (2009) Translational research in the development of novel sepsis therapeutics: logical deductivereasoning or mission impossible? Crit Care Med 37(1 Suppl):S10–S15. doi:10.1097/CCM.0b013e3181921497
Rudiger A, Dyson A, Felsmann K, et al. (2013) Early functional and transcriptomic changes in the myocardium predict outcome in a long-term rat model of sepsis. Clin Sci (Lond). 124(6):391-401. doi: 10.1042/CS20120334
Thongboonkerd V (2013) The promise and challenge of systems biology in translational medicine. Clin Sci (Lond) 124(6):389–390. doi:10.1042/CS20120565
Schultz MJ, Spronk PE, Afessa B (2009) Evidence lost to treatment of critically-ill patients? Minerva Anestesiol 75(12):715–729
Kampmeier TG, Ertmer C, Rehberg S (2011) Translational research in sepsis—an ultimate challenge? Exp Transl Stroke Med 3:14. doi:10.1186/2040-7378-3-14
An G, Christley S (2012) Addressing the translational dilemma: dynamic knowledge representation of inflammation using agent-based modeling. Crit Rev Biomed Eng 40(4):323–340
Vodovotz Y, Csete M, Bartels J et al (2008) Translational systems biology of inflammation. PLoS Comput Biol 4(4):e1000014. doi:10.1371/journal.pcbi.1000014
Balestra GM, Legrande M, Ince C (2009) Microcirculation and mitochondria in sepsis: getting out of breath. Curr Opin Anaesthesiol 22(2):184–190
Schuetz P, Chiappa V, Briel M et al (2011) Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 171(15):1322–1331. doi:10.1001/archinternmed.2011.318
Nakada TA, Russell JA, Wellman H et al (2011) Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 139(5):1042–1049. doi:10.1378/chest.10-2517
Stallmach A, Hagel S, Bruns T, Bauer M (2012) Cut a long story too short: Challenges in clinical research. Dtsch Med Wochenschr 137(10):496–500
Bone RC, Fisher JC Jr, Clemmer TP et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Eng J Med 317:653–658
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix from Surviving Sepsis Campaign 2013
Appendix from Surviving Sepsis Campaign 2013
 | Bundles 2012 | Grade | ||
---|---|---|---|---|
 | Initial Resuscitation and Infection Issues | |||
Initial Resuscitation | ||||
1 | Protocolized, quantitative resuscitation of patients with sepsis-induced tissue hypoperfusion (defined in this document as hypotension persisting after initial fluid challenge or blood lactate concentration ≥4 mmol/L) Goals during the first 6 h of resuscitation: a) Central venous pressure 8–12 mm Hg b) Mean arterial pressure (MAP) ≥65 mm Hg c) Urine output ≥0.5 mL/kg/h d) Central venous (superior vena cava) or mixed venous oxygen saturation 70 or 65 %, respectively | 1C | ||
2 | In patients with elevated lactate levels targeting resuscitation to normalize lactate | 2C | ||
Screening for Sepsis and Performance Improvement | ||||
1 | Routine screening of potentially infected seriously ill patients for severe sepsis to allow earlier implementation of therapy | 1C | ||
2 | Hospital–based performance improvement efforts in severe sepsis | UG | ||
 | Diagnosis | |||
1 | Cultures as clinically appropriate before antimicrobial therapy if no significant delay (>45Â min) in the start of antimicrobial(s) | 1C | ||
At least two sets of blood cultures (both aerobic and anaerobic bottles) be obtained before antimicrobial therapy with at least 1 drawn percutaneously and 1 drawn through each vascular access device, unless the device was recently (<48Â h) inserted | 1C | |||
2 | Use of the 1,3 beta-D-glucan assay and mannan and anti-mannan antibody assays if available, and invasive candidiasis is in differential diagnosis of cause of infection | 2B | ||
2C | ||||
 | Imaging studies performed promptly to confirm a potential source of infection | UG | ||
 | Antimicrobial Therapy | |||
1 | Administration of effective intravenous antimicrobials within the first hour of recognition of septic shock | 1B | ||
Administration of effective intravenous antimicrobials within the first hour of recognition of severe sepsis without septic shock | 1C | |||
2a | Initial empiric anti-infective therapy of one or more drugs that have activity against all likely pathogens (bacterial and/or fungal or viral) and that penetrate in adequate concentrations into tissues presumed to be the source of sepsis | 1B | ||
2b | Antimicrobial regimen should be reassessed daily for potential deescalation | 1B | ||
3 | Use of low procalcitonin levels or similar biomarkers to assist the clinician in the discontinuation of empiric antibiotics in patients who initially appeared septic, but have no subsequent evidence of infection | 2C | ||
4a | Combination empirical therapy for neutropenic patients with severe sepsis | 2B | ||
Combination empirical therapy for patients with difficult-to-treat, multidrug-resistant bacterial pathogens such as Acinetobacter and Pseudomonas spp. | 2B | |||
Combination therapy with an extended spectrum beta-lactam and either an aminoglycoside or a fluoroquinolone for patients with severe infections associated with respiratory failure and septic shock, for P. aeruginosa bacteremia | 2B | |||
A combination of beta-lactam and macrolide for patients with septic shock from bacteremic Streptococcus pneumoniae infections | 2B | |||
4b | Empiric combination therapy should not be administered for more than 3–5 days. De-escalation to the most appropriate single therapy should be performed as soon as the susceptibility profile is known | 2B | ||
5 | Duration of therapy typically 7–10 days; longer courses may be appropriate in patients who have a slow clinical response, undrainable foci of infection, bacteremia with S. aureus; some fungal and viral infections or immunologic deficiencies, including neutropenia | 2C | ||
6 | Antiviral therapy initiated as early as possible in patients with severe sepsis or septic shock of viral origin | Grade 2C | ||
7 | Antimicrobial agents should not be used in patients with severe inflammatory states determined to be of noninfectious cause | UG | ||
Source Control | ||||
1 | A specific anatomical diagnosis of infection requiring consideration for emergent source control be sought and diagnosed or excluded as rapidly as possible, and intervention be undertaken for source control within the first 12Â h after the diagnosis is made, if feasible | 1C | ||
2 | When infected peripancreatic necrosis is identified as a potential source of infection, definitive intervention is best delayed until adequate demarcation of viable and nonviable tissues has occurred | 2B | ||
3 | When source control in a severely septic patient is required, the effective intervention associated with the least physiologic insult should be used (e.g., percutaneous rather than surgical drainage of an abscess) (UG) | UG | ||
4 | If intravascular access devices are a possible source of severe sepsis or septic shock, they should be removed promptly after other vascular access has been established (UG) | UG | ||
Infection Prevention | ||||
1a | Selective oral decontamination and SDD should be introduced and investigated as a method to reduce the incidence of ventilator-associated pneumonia; this infection control measure can then be instituted in health care settings and regions where this methodology is found to be effective | 2B | ||
1b | Oral chlorhexidine gluconate be used as a form of oropharyngeal decontamination to reduce the risk of ventilator-associated pneumonia in ICU patients with severe sepsis | 2B | ||
Fluid Therapy of Severe Sepsis | ||||
1 | Crystalloids as the initial fluid of choice in the resuscitation of severe sepsis and septic shock | 1B | ||
2 | Against the use of hydroxyethyl starches for fluid resuscitation of severe sepsis and septic shock | 1B | ||
3 | Albumin in the fluid resuscitation of severe sepsis and septic shock when patients require substantial amounts of crystalloids | 2C | ||
4 | Initial fluid challenge in patients with sepsis-induced tissue hypoperfusion with suspicion of hypovolemia to achieve a minimum of 30Â mL/kg of crystalloids (a portion of this may be albumin equivalent). More rapid administration and greater amounts of fluid may be needed in some patients | 1C | ||
5 | Fluid challenge technique be applied wherein fluid administration is continued as long as there is hemodynamic improvement either based on dynamic (e.g., change in pulse pressure, stroke volume variation) or static (e.g., arterial pressure, heart rate) variables | UG | ||
Vasopressors | ||||
1 | Vasopressor therapy initially to target a mean arterial pressure (MAP) of 65Â mm Hg | 1C | ||
2 | Norepinephrine as the first choice vasopressor | 1B | ||
3 | Epinephrine (added to and potentially substituted for norepinephrine) when an additional agent is needed to maintain adequate blood pressure | 2B | ||
4 | Vasopressin 0.03Â units/min can be added to norepinephrine (NE) with intent of either raising MAP or decreasing NE dosage | UG | ||
5 | Low dose vasopressin is not recommended as the single initial vasopressor for treatment of sepsis-induced hypotension and vasopressin doses higher than 0.03–0.04 units/min should be reserved for salvage therapy (failure to achieve adequate MAP with other vasopressor agents) | UG | ||
6 | Dopamine as an alternative vasopressor agent to norepinephrine only in highly selected patients (e.g., patients with low risk of tachyarrhythmias and absolute or relative bradycardia) | 2C | ||
7 | Phenylephrine is not recommended in the treatment of septic shock except in circumstances where: | 1C | ||
(a) norepinephrine is associated with serious arrhythmias | ||||
(b) cardiac output is known to be high and blood pressure persistently low or | ||||
(c) as salvage therapy when combined inotrope/vasopressor drugs and low dose vasopressin have failed to achieve MAP target | ||||
8 | Low-dose dopamine should not be used for renal protection | 1A | ||
9 | All patients requiring vasopressors have an arterial catheter placed as soon as practical if resources are available (UG) | Â | ||
Inotropic Therapy | ||||
1 | A trial of dobutamine infusion up to 20 μg/kg/min be administered or added to vasopressor (if in use) in the presence of (a) myocardial dysfunction as suggested by elevated cardiac filling pressures and low cardiac output, or (b) ongoing signs of hypoperfusion, despite achieving adequate intravascular volume and adequate MAP | 1C | ||
2 | Not using a strategy to increase cardiac index to predetermined supranormal levels | 1B | ||
Corticosteroids | ||||
1 | Not using intravenous hydrocortisone to treat adult septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability (see goals for Initial Resuscitation). In case this is not achievable, we suggest intravenous hydrocortisone alone at a dose of 200Â mg per day | 2C | ||
2 | Not using the ACTH stimulation test to identify adults with septic shock who should receive hydrocortisone | 2B | ||
3 | In treated patients hydrocortisone tapered when vasopressors are no longer required | 2D | ||
4 | Corticosteroids not be administered for the treatment of sepsis in the absence of shock | 1D | ||
5 | When hydrocortisone is given, use continuous flow | 2D | ||
Blood Product Administration | ||||
1 | Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, acute hemorrhage, or ischemic heart disease, we recommend that red blood cell transfusion occur only when hemoglobin concentration decreases to <7.0 g/dL to target a hemoglobin concentration of 7.0–9.0 g/dL in adults | 1B | ||
2 | Not using erythropoietin as a specific treatment of anemia associated with severe sepsis | 1B | ||
3 | Fresh frozen plasma not be used to correct laboratory clotting abnormalities in the absence of bleeding or planned invasive procedures | 2D | ||
4 | Not using antithrombin for the treatment of severe sepsis and septic shock | 1B | ||
5 | In patients with severe sepsis, administer platelets prophylactically when counts are <10,000/mm3 (10 × 109/L) in the absence of apparent bleeding. We suggest prophylactic platelet transfusion when counts are <20,000/mm3 (20 × 109/L) if the patient has a significant risk of bleeding. Higher platelet counts (≥50,000/mm3 [50 × 109/L]) are advised for active bleeding, surgery, or invasive procedures | 2D | ||
Immunoglobulins | ||||
 | Not using intravenous immunoglobulins in adult patients with severe sepsis or septic shock | 2B | ||
Selenium | ||||
 | Not using intravenous selenium for the treatment of severe sepsis | 2C | ||
History of Recommendations Regarding Use of rhAPC | ||||
 | The specific mechanisms by which drotrecogin alfa (activated) exerts its effect on survival in patients with severe sepsis are controversial, not completely understood and the evolution of SSC RECOMENDATIONS not recommended the use of rhAPC |  | ||
Mechanical Ventilation of Sepsis-Induced ARDS | ||||
1 | Target a tidal volume of 6Â mL/kg predicted body weight in patients with sepsis-induced ARDS (vs. 12Â mL/kg) | 1A | ||
2 | Plateau pressures be measured in patients with ARDS and initial upper limit goal for plateau pressures in a passively inflated lung be ≤30 cm H2O | 1B | ||
3 | Positive end-expiratory pressure (PEEP) be applied to avoid alveolar collapse at end expiration (atelectotrauma) | 1B | ||
4 | Strategies based on higher rather than lower levels of PEEP be used for patients with sepsis-induced moderate or severe ARDS | 2C | ||
5 | Recruitment maneuvers be used in sepsis patients with severe refractory hypoxemia | 2C | ||
6 | Prone positioning be used in sepsis-induced ARDS patients with a Pao2/Fio2 ratio ≤100 mm Hg in facilities that have experience with such practices | 2B | ||
7 | That mechanically ventilated sepsis patients be maintained with the head of the bed elevated to 30–45° to limit aspiration risk and to prevent the development of ventilator-associated pneumonia | 1B | ||
8 | That noninvasive mask ventilation (NIV) be used in that minority of sepsis-induced ARDS patients in whom the benefits of NIV have been carefully considered and are thought to outweigh the risks | 2B | ||
9 | That a weaning protocol be in place and that mechanically ventilated patients with severe sepsis undergo spontaneous breathing trials regularly to evaluate the ability to discontinue mechanical ventilation when they satisfy the following criteria: | 1A | ||
(a) arousable | Â | Â | ||
(b) hemodynamically stable (without vasopressor agents) | Â | |||
(c) no new potentially serious conditions | Â | Â | ||
(d) low ventilatory and end-expiratory pressure requirements | Â | |||
(e) low Fio2 requirements which can be met safely delivered with a face mask or nasal cannula | ||||
If the spontaneous breathing trial is successful, consideration should be given for extubation | ||||
10 | Against the routine use of the pulmonary artery catheter for patients with sepsis induced ARDS | 1A | ||
11 | A conservative rather than liberal fluid strategy for patients with established sepsis-induced ARDS who do not have evidence of tissue hypoperfusion | 1C | ||
12 | In the absence of specific indications such as bronchospasm, not using beta 2-agonists for treatment of sepsis-induced ARDS | 1B | ||
Sedation, Analgesia, and Neuromuscular Blockade in Sepsis | ||||
1 | Continuous or intermittent sedation be minimized in mechanically ventilated sepsis patients, targeting specific titration endpoints | 1B | ||
2 | Neuromuscular blocking agents (NMBAs) be avoided if possible in the septic patient without ARDS due to the risk of prolonged neuromuscular blockade following discontinuation. If NMBAs must be maintained, either intermittent bolus as required or continuous infusion with train-of-four monitoring of the depth of blockade should be used | 1C | ||
3 | A short course of NMBA of not greater than 48 h for patients with early sepsis-induced ARDS and a PaO2/Fio2 <150 mm Hg | 2C | ||
Glucose Control | ||||
1 | A protocolized approach to blood glucose management in ICU patients with severe sepsis commencing insulin dosing when 2 consecutive blood glucose levels are >180 mg/dL. This protocolized approach should target an upper blood glucose ≤180 mg/dL rather than an upper target blood glucose ≤110 mg/dL | 1A | ||
2 | Blood glucose values be monitored every 1–2 h until glucose values and insulin infusion rates are stable and then every 4 h thereafter | 1C | ||
3 | Glucose levels obtained with point-of-care testing of capillary blood be interpreted with caution, as such measurements may not accurately estimate arterial blood or plasma glucose values | UG | ||
Renal Replacement Therapy | ||||
1 | Continuous renal replacement therapies and intermittent hemodialysis are equivalent in patients with severe sepsis and acute renal failure | 2B | ||
2 | Use continuous therapies to facilitate management of fluid balance in hemodynamically unstable septic patients | 2D | ||
Bicarbonate Therapy | ||||
 | Not using sodium bicarbonate therapy for the purpose of improving hemodynamics or reducing vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with pH ≥ 7.15 | 2B | ||
Deep Vein Thrombosis Prophylaxis | ||||
1 | Patients with severe sepsis receive daily pharmacoprophylaxis against venous thromboembolism (VTE) with daily subcutaneous low-molecular weight heparin (LMWH) | 1B | ||
 | (a) versus twice daily UFH | 1B | ||
 | (b) versus three times daily UFH | 2C | ||
If creatinine clearance is < 30 mL/min, use | (a) dalteparin | 1A | ||
 | (b) another form of LMWH that has a low degree of renal metabolism | 2C | ||
 |  | (c) UFH | 1A | |
2 | Patients with severe sepsis be treated with a combination of pharmacologic therapy and intermittent pneumatic compression devices whenever possible | 2C | ||
3 | Septic patients who have a contraindication for heparin use (e.g., thrombocytopenia, severe coagulopathy, active bleeding, and recent intracerebral hemorrhage) | Â | ||
a) not receive pharmacoprophylaxis | 1B | |||
b) receive mechanical prophylactic treatment, such as graduated compression stockings or intermittent compression devices, unless contraindicated. | 2C | |||
c) When the risk decreases start pharmacoprophylaxis | 2C | |||
Stress Ulcer Prophylaxis | ||||
1 | Stress ulcer prophylaxis using H2 blocker or proton pump inhibitor be given to patients with severe sepsis/septic shock who have bleeding risk factors | 1B | ||
2 | When stress ulcer prophylaxis is used, proton pump inhibitors rather than H2RA | 2D | ||
3 | Patients without risk factors do not receive prophylaxis | 2B | ||
Nutrition | ||||
1 | Administer oral or enteral (if necessary) feedings, as tolerated, rather than either complete fasting or provision of only intravenous glucose within the first 48Â h after a diagnosis of severe sepsis/septic shock | 2C | ||
2 | Avoid mandatory full caloric feeding in the first week but rather suggest low dose feeding (e.g., up to 500 calories per day), advancing only as tolerated | 2B | ||
3 | Use intravenous glucose and enteral nutrition rather than total parenteral nutrition (TPN) alone or parenteral nutrition in conjunction with enteral feeding in the first 7Â days after a diagnosis of severe sepsis/septic shock | 2B | ||
4 | Use nutrition with no specific immunomodulating supplementation rather than nutrition providing specific immunomodulating supplementation in patients with severe sepsis | 2C | ||
Setting Goals of Care | ||||
1 | Discuss goals of care and prognosis with patients and families | 1B | ||
2 | Incorporate goals of care into treatment and end-of-life care planning, utilizing palliative care principles where appropriate | 1B | ||
3 | Address goals of care as early as feasible, but no later than within 72Â h of ICU admission | 2C |
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this paper
Cite this paper
Gullo, A., Celestre, C.M., Paratore, A.L., Silvestri, L., van Saene, H.K. (2014). Sepsis and Organ(s) Dysfunction. In: Gullo, A. (eds) Anaesthesia, Pharmacology, Intensive Care and Emergency A.P.I.C.E.. Springer, Milano. https://doi.org/10.1007/978-88-470-5516-2_14
Download citation
DOI: https://doi.org/10.1007/978-88-470-5516-2_14
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5515-5
Online ISBN: 978-88-470-5516-2
eBook Packages: MedicineMedicine (R0)